Biological and chemical diversity go hand in hand: Basidiomycota as source of new pharmaceuticals and agrochemicals.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sandargo, BirtheChepkirui, Clara
Cheng, Tian
Chaverra-Muñoz, Lillibeth
Thongbai, Benjarong
Stadler, Marc
Hüttel, Stephan
Issue Date
2019-02-07
Metadata
Show full item recordAbstract
The Basidiomycota constitutes the second largest higher taxonomic group of the Fungi after the Ascomycota and comprises over 30.000 species. Mycelial cultures of Basidiomycota have already been studied since the 1950s for production of antibiotics and other beneficial secondary metabolites. Despite the fact that unique and selective compounds like pleuromutilin were obtained early on, it took several decades more until they were subjected to a systematic screening for antimicrobial and anticancer activities. These efforts led to the discovery of the strobilurins and several hundreds of further compounds that mainly constitute terpenoids. In parallel the traditional medicinal mushrooms of Asia were also studied intensively for metabolite production, aimed at finding new therapeutic agents for treatment of various diseases including metabolic disorders and the central nervous system. While the evaluation of this organism group has in general been more tedious as compared to the Ascomycota, the chances to discover new metabolites and to develop them further to candidates for drugs, agrochemicals and other products for the Life Science industry have substantially increased over the past decade. This is owing to the revolutionary developments in -OMICS techniques, bioinformatics, analytical chemistry and biotechnological process technology, which are steadily being developed further. On the other hand, the new developments in polythetic fungal taxonomy now also allow a more concise selection of previously untapped organisms. The current review is dedicated to summarize the state of the art and to give an outlook to further developments.Citation
Biotechnol Adv. 2019 Nov 1;37(6):107344. doi: 10.1016/j.biotechadv.2019.01.011. Epub 2019 Feb 7.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
ElsevierJournal
Biotechnology advancesPubMed ID
30738916Type
ReviewOther
Language
enEISSN
1873-1899ae974a485f413a2113503eed53cd6c53
10.1016/j.biotechadv.2019.01.011
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Recent progress in biodiversity research on the Xylariales and their secondary metabolism.
- Authors: Becker K, Stadler M
- Issue date: 2021 Jan
- Extracellular polysaccharides from Ascomycota and Basidiomycota: production conditions, biochemical characteristics, and biological properties.
- Authors: Osińska-Jaroszuk M, Jarosz-Wilkołazka A, Jaroszuk-Ściseł J, Szałapata K, Nowak A, Jaszek M, Ozimek E, Majewska M
- Issue date: 2015 Dec
- Fungi as a source of natural coumarins production.
- Authors: Costa TM, Tavares LBB, de Oliveira D
- Issue date: 2016 Aug
- Medicinal fungi: a source of antiparasitic secondary metabolites.
- Authors: Lenzi J, Costa TM, Alberton MD, Goulart JAG, Tavares LBB
- Issue date: 2018 Jul
- Insights in Fungal Bioprospecting in Mexico.
- Authors: Mata R, Figueroa M, Rivero-Cruz I, Macías-Rubalcava ML
- Issue date: 2018 Jul